BACKGROUND: Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectious virus isolation in outpatients with coronavirus disease 2019 (COVID-19) has been associated with viral RNA levels and symptom duration, little is known about the host, disease, and viral determinants of infectious virus detection. METHODS: COVID-19 adult outpatients were enrolled within 7 days of symptom onset. Clinical symptoms were recorded via patient diary. Nasopharyngeal swabs were collected to quantitate SARS-CoV-2 RNA by reverse transcriptase polymerase chain reaction and for infectious virus isolation in Vero E6-cells. SARS-CoV-2 antibodies were measured in serum using a validated ELISA assay. RESULTS: Among 204 participants with mild-to-moderate symptomatic COVID-19, the median nasopharyngeal viral RNA was 6.5 (interquartile range [IQR] 4.7-7.6 log10 copies/mL), and 26% had detectable SARS-CoV-2 antibodies (immunoglobulin (Ig)A, IgM, IgG, and/or total Ig) at baseline. Infectious virus was recovered in 7% of participants with SARS-CoV-2 antibodies compared to 58% of participants without antibodies (prevalence ratio [PR] = 0.12, 95% confidence interval [CI]: .04, .36; P = .00016). Infectious virus isolation was also associated with higher levels of viral RNA (mean RNA difference +2.6 log10, 95% CI: 2.2, 3.0; P < .0001) and fewer days since symptom onset (PR = 0.79, 95% CI: .71, .88 per day; P < .0001). CONCLUSIONS: The presence of SARS-CoV-2 antibodies is strongly associated with clearance of infectious virus. Seropositivity and viral RNA levels are likely more reliable markers of infectious virus clearance than subjective measure of COVID-19 symptom duration. Virus-targeted treatment and prevention strategies should be administered as early as possible and ideally before seroconversion. CLINICAL TRIALS REGISTRATION: NCT04405570.
BACKGROUND: Although severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectious virus isolation in outpatients with coronavirus disease 2019 (COVID-19) has been associated with viral RNA levels and symptom duration, little is known about the host, disease, and viral determinants of infectious virus detection. METHODS: COVID-19 adult outpatients were enrolled within 7 days of symptom onset. Clinical symptoms were recorded via patient diary. Nasopharyngeal swabs were collected to quantitate SARS-CoV-2 RNA by reverse transcriptase polymerase chain reaction and for infectious virus isolation in Vero E6-cells. SARS-CoV-2 antibodies were measured in serum using a validated ELISA assay. RESULTS: Among 204 participants with mild-to-moderate symptomatic COVID-19, the median nasopharyngeal viral RNA was 6.5 (interquartile range [IQR] 4.7-7.6 log10 copies/mL), and 26% had detectable SARS-CoV-2 antibodies (immunoglobulin (Ig)A, IgM, IgG, and/or total Ig) at baseline. Infectious virus was recovered in 7% of participants with SARS-CoV-2 antibodies compared to 58% of participants without antibodies (prevalence ratio [PR] = 0.12, 95% confidence interval [CI]: .04, .36; P = .00016). Infectious virus isolation was also associated with higher levels of viral RNA (mean RNA difference +2.6 log10, 95% CI: 2.2, 3.0; P < .0001) and fewer days since symptom onset (PR = 0.79, 95% CI: .71, .88 per day; P < .0001). CONCLUSIONS: The presence of SARS-CoV-2 antibodies is strongly associated with clearance of infectious virus. Seropositivity and viral RNA levels are likely more reliable markers of infectious virus clearance than subjective measure of COVID-19 symptom duration. Virus-targeted treatment and prevention strategies should be administered as early as possible and ideally before seroconversion. CLINICAL TRIALS REGISTRATION: NCT04405570.
Authors: Timothy P Sheahan; Amy C Sims; Shuntai Zhou; Rachel L Graham; Andrea J Pruijssers; Maria L Agostini; Sarah R Leist; Alexandra Schäfer; Kenneth H Dinnon; Laura J Stevens; James D Chappell; Xiaotao Lu; Tia M Hughes; Amelia S George; Collin S Hill; Stephanie A Montgomery; Ariane J Brown; Gregory R Bluemling; Michael G Natchus; Manohar Saindane; Alexander A Kolykhalov; George Painter; Jennifer Harcourt; Azaibi Tamin; Natalie J Thornburg; Ronald Swanstrom; Mark R Denison; Ralph S Baric Journal: Sci Transl Med Date: 2020-04-06 Impact factor: 17.956
Authors: Bina Choi; Manish C Choudhary; James Regan; Jeffrey A Sparks; Robert F Padera; Xueting Qiu; Isaac H Solomon; Hsiao-Hsuan Kuo; Julie Boucau; Kathryn Bowman; U Das Adhikari; Marisa L Winkler; Alisa A Mueller; Tiffany Y-T Hsu; Michaël Desjardins; Lindsey R Baden; Brian T Chan; Bruce D Walker; Mathias Lichterfeld; Manfred Brigl; Douglas S Kwon; Sanjat Kanjilal; Eugene T Richardson; A Helena Jonsson; Galit Alter; Amy K Barczak; William P Hanage; Xu G Yu; Gaurav D Gaiha; Michael S Seaman; Manuela Cernadas; Jonathan Z Li Journal: N Engl J Med Date: 2020-11-11 Impact factor: 91.245
Authors: Lauren M Rossen; Amy M Branum; Farida B Ahmad; Paul Sutton; Robert N Anderson Journal: MMWR Morb Mortal Wkly Rep Date: 2020-10-23 Impact factor: 17.586
Authors: Ji Hoon Baang; Christopher Smith; Carmen Mirabelli; Andrew L Valesano; David M Manthei; Michael A Bachman; Christiane E Wobus; Michael Adams; Laraine Washer; Emily T Martin; Adam S Lauring Journal: J Infect Dis Date: 2021-01-04 Impact factor: 5.226
Authors: Matthew S Buckland; James B Galloway; Caoimhe Nic Fhogartaigh; Luke Meredith; Nicholas M Provine; Stuart Bloor; Ane Ogbe; Wioleta M Zelek; Anna Smielewska; Anna Yakovleva; Tiffeney Mann; Laura Bergamaschi; Lorinda Turner; Frederica Mescia; Erik J M Toonen; Carl-Philipp Hackstein; Hossain Delowar Akther; Vinicius Adriano Vieira; Lourdes Ceron-Gutierrez; Jimstan Periselneris; Sorena Kiani-Alikhan; Sofia Grigoriadou; Devan Vaghela; Sara E Lear; M Estée Török; William L Hamilton; Joanne Stockton; Josh Quick; Peter Nelson; Michael Hunter; Tanya I Coulter; Lisa Devlin; John R Bradley; Kenneth G C Smith; Willem H Ouwehand; Lise Estcourt; Heli Harvala; David J Roberts; Ian B Wilkinson; Nick Screaton; Nicholas Loman; Rainer Doffinger; Paul A Lyons; B Paul Morgan; Ian G Goodfellow; Paul Klenerman; Paul J Lehner; Nicholas J Matheson; James E D Thaventhiran Journal: Nat Commun Date: 2020-12-14 Impact factor: 17.694
Authors: Meagan E Deming; Tracy Q Dong; Vaidehi Agrawal; Margaret G Mills; Meei Li W Huang; Alexander L Greninger; Keith R Jerome; Mark H Wener; Michael K Paasche-Orlow; Patricia Kissinger; Alfred Luk; Risa M Hoffman; Jenell Stewart; Angelica C Kottkamp; Anna Bershteyn; Helen Y Chu; Helen C Stankiewicz Karita; Christine M Johnston; Anna Wald; Ruanne Barnabas; Elizabeth R Brown; Kathleen M Neuzil Journal: J Infect Dis Date: 2022-09-13 Impact factor: 7.759